AzTrials
AzTrials

Smoking CessationPhase 1NCT02237898

Harnessing the Power of Technology: MOMBA for Postpartum Smoking

A Phase 1 study testing MoMba Live Long app & Sensordrone™ carbon-monoxide sensor, Office contingency management and Sensordrone™ carbon-monoxide sensor in people with Smoking Cessation, run by Yale University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Through a smartphone platform, financial incentives for smoking abstinence in postpartum women can be delivered remotely, thus minimizing the need for participants to come to the office to receive traditional contingency management. Read more about this study

Who is it for?
Ages 18 to 50 years, women onlyHealthy volunteers can take part
Conditions the study is for
Smoking Cessation
What is being tested?
MoMba Live Long app & Sensordrone™ carbon-monoxide sensor, Office contingency management and Sensordrone™ carbon-monoxide sensor
Could I receive a placebo?
No, everyone receives an active treatment
How many people
26 participants
Where
1 siteUnited States
Study dates
10 Feb 2017to 13 May 2019
Phase
Phase 1
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Women who are over the age of 18
  • Speak English
  • Second or third trimester of pregnancy
  • Smoking in the third trimester of pregnancy
  • No complicating general medical or psychiatric conditions (including marijuana use).

Who cannot join

  • Receiving other smoking cessation medication
  • Planning to move out of New Haven in the next 15 months
  • Actively suicidal, psychotic or unable to provide informed consent

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Center for Wellbeing of Women and Mothers, 40 Temple Street, Ste 6B, Yale University

    New Haven, Connecticut, 06510

Other trials in United States

About this study

Official title: SCH: INT: Harnessing the Power of Technology: MOMBA for Postpartum Smoking

Through a smartphone platform, financial incentives for smoking abstinence in postpartum women can be delivered remotely, thus minimizing the need for participants to come to the office to receive traditional contingency management.

Read the detailed description

The specific aims of the proposal are:

  1. To develop through a 15-month pilot study, a novel smartphone-based system, Momba Smoking, that can be used in further relapse prevention trials for postpartum smokers.
  2. To determine, through a pilot randomized controlled trial, the potential feasibility, acceptability, and methodological parameters that are necessary to design a subsequent, appropriately powered, randomized controlled trial of the Momba Smoking smartphone-based system.
  3. To advance discovery and understanding on the use of technology to translate smoking cessation interventions from clinical to community settings through the training of the next generation of scientists.
Being tested
MoMba Live Long app & Sensordrone™ carbon-monoxide sensor, Office contingency management, Sensordrone™ carbon-monoxide sensor, MoMba Live Long Smartphone application
Keywords
Tobacco cessation
Medical subject headings
Smoking Cessation, Tobacco Use Cessation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MoMba Live Long app & Sensordrone™ carbon-monoxide sensorBehavioural

    MoMba Live Long application \& Sensordrone™ carbon-monoxide sensor to deliver contingency management remotely

  • Office contingency managementBehavioural

    A control group which will receive financial incentives at an in-person office/clinic visit based on expired CO levels obtained through the piCO sensor.

  • Sensordrone™ carbon-monoxide sensorDevice

    A custom breath CO meter built by Sensorcon Inc. (Sensordrone, part No. SDRONEG1) that uses an electrochemical CO gas sensor to measure environmental CO. The Sensordrone is accurate to within 10% with a resolution of 1 parts per million (ppm). The Sensordrone pairs via Bluetooth with the MoMba Live Long application.

  • MoMba Live Long Smartphone applicationDevice

    The MoMba Live Long app provides an interface for the Sensordrone which allows participants to complete a breath test and see results of smoking status. The app verifies the user is correctly taking the tests by recording pictures using the front facing camera as well as recording audio to verify that the participants where exhaling while taking the test. The app also provided a platform for social interaction based on a previous system where app users can interact with each other and provide support during the quitting process.

Study groups in NCT02237898
Study groupRoleWhat they receive
MoMba Contingency ManagementExperimentalStudy will provide access to the web-based MoMba Live Long application \& Sensodrone™ carbon-monoxide sensor for purposes of researching the acceptability of the smartphone application, operating and functioning of it, and providing remote contingency management for smoking cessation to postpartum women.
Receives: Behavioral: MoMba Live Long app & Sensordrone™ carbon-monoxide sensor; Device: Sensordrone™ carbon-monoxide sensor; Device: MoMba Live Long Smartphone application
Office contingency managementActive comparatorTraditional contingency management with financial incentives delivered in-person in the office for smoking cessation to postpartum women
Receives: Behavioral: Office contingency management; Device: Sensordrone™ carbon-monoxide sensor

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Acceptability

    Primary Outcome - Acceptability of the delivery of financial incentives for smoking abstinence in postpartum women through a smartphone platform as compared to traditional, in office contingency management. Acceptability of the smartphone application to low-income, pregnant women defined by the percentage of women who would recommend the site to a friend.

    Question: "How likely is it that you would recommend MoMba LiveLong to a friend who wants to stop smoking?"

    Measured: 3 and 9 months

  2. Enrollment Rate

    Primary Outcome - Feasibility of the delivery of financial incentives for smoking abstinence in postpartum women through a smartphone platform as compared to traditional, in office contingency management. Feasibility: participation rate of > 60% for eligible women between screening and enrollment. Number of women who were eligible from screening that completed an intake.

    Measured: 15 months

  3. Remote Detection

    Primary outcome is the correlation coefficient. The correlation coefficient was calculated between the piCO+™ and the Sensordrone™ specific to expired CO measurement and verified through urine cotinine levels. Data for all three instruments was collected during week 1 visits 1-5, 3 month, 9 month and 15 month assessments.

    Measured: 15 months

  4. Retention: Number of Participants Remaining in Study at 12 Weeks

    Primary Outcome - Feasibility of the delivery of financial incentives for smoking abstinence in postpartum women through a smartphone platform as compared to traditional, in office contingency management. Feasibility: retention set at 80% for the Momba Smoking group. Number of participants in the intervention group (MoMba Contingency Management) and number of participants in the control group (office contingency management) who remained in the study at the end of contingency management (12 weeks).

    Measured: 15 months

  5. Visit Attendance / Challenge Completion

    Primary Outcome - Feasibility of the delivery of financial incentives for smoking abstinence in postpartum women through a smartphone platform as compared to traditional, in office contingency management. Feasibility: challenge completion and in-office visit attendance to assess compliance.

    MoMba Contingency Management: Number of breath tests completed among participants who remained enrolled at the end of 12 weeks.

    Office Contingency Management: Number of breath tests (corresponds to office visits) completed among participants who remained enrolled at the end of 12 weeks.

    Measured: 15 months

Secondary outcomes (3)
  1. Number of Participants With Short Term Abstinence From Smoking

    Secondary outcome - Short term abstinence from smoking. Immediate smoking prevalence as determined by # of negative breath tests and self-reports; the pilot will also utilize urine tests to measure negative cotinine levels.

    Measured: 3 months

  2. Number of Participants With Long Term Abstinence From Smoking at 9 Month Follow-Up

    Secondary outcome - Long term abstinence from smoking equals 7-day point prevalence determined through # of negative breath tests and self-reports based on the Timeline Follow Back.

    Measured: 9 months

  3. Number of Participants With Long Term Abstinence From Smoking at 15 Month Follow-Up

    Secondary outcome - Long term abstinence from smoking equals 7-day point prevalence determined through # of negative breath tests and self-reports based on the Timeline Follow Back.

    Measured: 15 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Sep 2014 (estimated)
  2. Study start10 Feb 2017
  3. Primary completion13 May 2019
  4. Study completion13 May 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
26 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02237898
Sponsor's protocol ID
1407014326
Other IDs
5R01CA195654
Status last verified
May 2020
First submitted
9 Sep 2014
Last updated
21 May 2020
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Valencia S, Callinan L, Shic F, Smith M. Evaluation of the MoMba Live Long Remote Smoking Detection System During and After Pregnancy: Development and Usability Study. JMIR Mhealth Uhealth. 2020 Nov 24;8(11):e18809. doi: 10.2196/18809.

    PubMed 33231550

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing MoMba Live Long app & Sensordrone™ carbon-monoxide sensor, Office contingency management and Sensordrone™ carbon-monoxide sensor in people with Smoking Cessation, run by Yale University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 May 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 21 May 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Acceptability (time frame: 3 and 9 months). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02237898, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 May 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in